Alberts D S
Department of Medicine and Arizona Cancer Center, College of Medicine, University of Arizona, Tucson, USA.
Semin Oncol. 1999 Apr;26(2 Suppl 7):125-8.
Cisplatin is one of the most commonly used chemotherapeutic agents to treat gynecologic cancers. However, many patients treated with platinum therapy experience significant toxicities, including neurotoxicity, ototoxicity, and/or nephrotoxicity. Clinical trials have documented the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced ovarian cancer. In these trials, the incidence and severity of many dose-limiting toxicities was reduced significantly by the concomitant administration of amifostine. The management of advanced ovarian, cervical, and endometrial cancers provides many opportunities for future applications of amifostine. Several studies that are being initiated in the United States involve maintaining platinum dose intensity, reducing toxicities, and developing chemotherapeutic combinations that would otherwise have to be avoided without the use of a cytoprotective agent such as amifostine.
顺铂是治疗妇科癌症最常用的化疗药物之一。然而，许多接受铂类疗法的患者会出现严重的毒性反应，包括神经毒性、耳毒性和/或肾毒性。临床试验已证明氨磷汀在晚期卵巢癌患者中作为一种细胞保护剂可对抗顺铂诱导的毒性。在这些试验中，同时给予氨磷汀可显著降低许多剂量限制性毒性的发生率和严重程度。晚期卵巢癌、宫颈癌和子宫内膜癌的治疗为氨磷汀的未来应用提供了许多机会。美国正在开展的几项研究涉及维持铂类药物的剂量强度、降低毒性以及开发化疗联合方案，否则在不使用氨磷汀这种细胞保护剂的情况下这些联合方案将不得不被避免。
